About two years ago, the FDA began tightening the statistical standard that companies must meet to demonstrate the efficacy of antibiotics in clinical trials. Meeting that heightened burden of proof meant, in certain instances, substantially increasing trial size and duration-leading some drug companies to drop particular development programs, and even pare back on their development of antibacterials altogether. At the time, the FDA's treatment of antibiotics seemed, to many, part of a broader trend towards a more cautious and conservative approach to drug approval. But it turns out that rather than evidencing a concerted agency effort to more closely scrutinize the effectiveness of antimicrobials, the new policy was apparently instituted by a statistical-minded faction within the FDA whose influence shot up in the absence of strong central leadership. Indeed, that intra-agency power balance has now apparently shifted in favor of medically oriented officials who are more sympathetic to the practical problems faced by antibiotic drugmakers. But while pharmaceutical company officials voice optimism that they will be able to work out a reasonable new set of efficacy guidelines with the FDA, there's a lingering concern that the power vacuum at the top of the agency will continue to create uncertainty and unpredictability for an industry whose long-term development cycles make it so dependent on regulatory consistency.
by Jeffrey Dvorin
"The United States Food and Drug Administration and the End of Antibiotics." So read the heading of a piece contained...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG
Understand who’s influencing access decisions and how pharma can engage strategically across the continent.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
